Big data analytics for prostate radiotherapy

Frontiers in Oncology

Volumn 6, Issue JUN, 2016, Pages

  Coates, James ^a   Souhami, Luis ^b   El Naqa, Issam ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Big data; Data mining; Machine learning; Radiotherapy; Systems radiobiology

Indexed keywords

ADENOCARCINOMA; ARTIFICIAL INTELLIGENCE; CANCER CONTROL; CANCER PROGNOSIS; CANCER RADIOTHERAPY; COMPUTER PROGRAM; DATA ANALYSIS SOFTWARE; DATA MINING; EPIGENETICS; GENETIC VARIABILITY; HUMAN; MACHINE LEARNING; MALE; MRNA EXPRESSION ASSAY; OUTCOME ASSESSMENT; PHYSICAL MODEL; PRINCIPAL COMPONENT ANALYSIS; PROSTATE CANCER; PROTEOMICS; REVIEW; RISK FACTOR; VALIDATION PROCESS;

EID: 84982788079     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00149     Document Type: Review

References (166)

1. UK CR. Prostate cancer statistics. Cancer Stat (2011). Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer#heading-Zero
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer (2013) 49:1374-403. doi:10.1016/j.ejca.2012.12.027
3. Network NCI. Treatment Routes in Prostate Cancer. Bristol, UK (2009).
4. Sriprasad S, Feneley MR, Thompson PM. History of prostate cancer treatment. Surg Oncol (2009) 18:185-91. doi:10.1016/j.suronc.2009.07.001
5. Bauman G, Rumble RB, Chen J, Loblaw A, Warde P, Members of the IMRT Indications Expert Panel. Intensity-modulated radiotherapy in the treatment of prostate cancer. Clin Oncol (R Coll Radiol) (2012) 24:461-73. doi:10.1016/j.clon.2012.05.002
6. Musunuru HB, Loblaw A. Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future direction. Future Oncol (2015) 11:819-31. doi:10.2217/fon.15.14
7. De Ruysscher D, Mark Lodge M, Jones B, Brada M, Munro A, Jefferson T, et al. Charged particles in radiotherapy: a 5-year update of a systematic review. Radiother Oncol (2012) 103:5-7. doi:10.1016/j.radonc.2012.01.003
8. Hummel S, Simpson EL, Hemingway P, Stevenson MD, Rees A. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Health Technol Assess (2010) 14:1-108, iii-iv. doi:10.3310/hta14470
9. Milano MT, Constine LS, Okunieff P. Normal tissue tolerance dose metrics for radiation therapy of major organs. Semin Radiat Oncol (2007) 17:131-40. doi:10.1016/j.semradonc.2006.11.009
10. Mundt A, Boeske JC. Intensity Modulated Radiation Therapy: A Clinical Perspective. Tokyo (2005). p. 151-2.
11. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys (2010) 76:S10-9. doi:10.1016/j.ijrobp.2009.07.1754
12. Bentzen SM, Parliament M, Deasy JO, Dicker A, Curran WJ, Williams JP, et al. Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects. Int J Radiat Oncol Biol Phys (2010) 76:S145-50. doi:10.1016/j.ijrobp.2009.08.076
13. Deasy JO, Mayo CS, Orton CG. Treatment planning evaluation and optimization should be biologically and not dose/volume based. Med Phys (2015) 42:2753-6. doi:10.1118/1.4916670
14. El Naqa I, Bradley J, Blanco AI, Lindsay PE, Vicic M, Hope A, et al. Multivariable modeling of radiotherapy outcomes, including dose-volume and clinical factors. Int J Radiat Oncol Biol Phys (2006) 64:1275-86. doi:10.1016/j.ijrobp.2005.11.022
15. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RGPM, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer (2012) 48:441-6. doi:10.1016/j.ejca.2011.11.036
16. Rosenstein BS, West CM, Bentzen SM, Alsner J, Andreassen CN, Azria D, et al. Radiogenomics: radiobiology enters the era of big data and team science. Int J Radiat Oncol Biol Phys (2014) 89:709-13. doi:10.1016/j.ijrobp.2014.03.009
17. Keetch DW, Humphrey PA, Smith DS, Stahl D, Catalona WJ. Clinical and pathological features of hereditary prostate cancer. J Urol (1996) 155:1841-3. doi:10.1016/S0022-5347(01)66024-5
18. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA (1994) 271:368-74. doi:10.1001/jama.271.5.368
19. Heppner GH, Miller BE. Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metastasis Rev (1983) 2:5-23. doi:10.1007/BF00046903
20. Mackinnon AC, Yan BC, Joseph LJ, et al. Molecular biology underlying the clinical heterogeneity of prostate cancer: an update. Arch Pathol Lab Med (2009) 133:1033-40. doi:10.1043/1543-2165-133.7.1033
21. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 18:11-22. doi:10.1016/j.ccr.2010.05.026
22. Kirkpatrick JP, Meyer JJ, Marks LB. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol (2008) 18:240-3. doi:10.1016/j.semradonc.2008.04.005
23. Jones B, Dale RG. Mathematical models of tumour and normal tissue response. Acta Oncol (1999) 38:883-93. doi:10.1080/028418699432572
24. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys (1999) 43:1095-101. doi:10.1016/S0360-3016(98)00438-6
25. Fowler J, Chappell R, Ritter M. Is α/β for prostate tumors really low? Int J Radiat Oncol Biol Phys (2001) 50:1021-31. doi:10.1016/S0360-3016(01)01607-8
26. Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol (2005) 44:265-76. doi:10.1080/02841860410002824
27. Dasu A. Is the α/β value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol (2007) 19:289-301. doi:10.1016/j.clon.2007.02.007
28. Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys (2005) 63:1463-8. doi:10.1016/j.ijrobp.2005.05.054
29. Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys (2010) 78:11-8. doi:10.1016/j.ijrobp.2009.07.1691
30. King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys (2009) 73:1043-8. doi:10.1016/j.ijrobp.2008.05.059
31. Vogelius IR, Bentzen SM. Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys (2013) 85:89-94. doi:10.1016/j.ijrobp.2012.03.004
32. Dörr W, Hendry JH. Consequential late effects in normal tissues. Radiother Oncol (2001) 61:223-31. doi:10.1016/S0167-8140(01)00429-7
33. Pinkawa M, Holy R, Piroth MD, Fischedick K, Schaar S, Székely-Orbán D, et al. Consequential late effects after radiotherapy for prostate cancer-a prospective longitudinal quality of life study. Radiat Oncol (2010) 5:27. doi:10.1186/1748-717X-5-27
34. Pinkawa M, Ribbing C, Djukic V, Klotz J, Holy R, Eble MJ. Early hematologic changes during prostate cancer radiotherapy predictive for late urinary and bowel toxicity. Strahlentherapie Und Onkol Organ Der Dtsch Röntgengesellschaft (2015) 191:771-7. doi:10.1007/s00066-015-0841-3
35. Drodge CS, Boychak O, Patel S, Usmani N, Amanie J, Parliament MB, et al. Acute toxicity of hypofractionated intensity-modulated radiotherapy for prostate cancer. Curr Oncol (2015) 22:e76-84. doi:10.3747/co.22.2247
36. Zietman AL. The Titanic and the iceberg: prostate proton therapy and health care economics. J Clin Oncol (2007) 25:3565-6. doi:10.1200/JCO.2007.11.9768
37. Yu JB, Soulos PR, Herrin J, Cramer LD, Potosky AL, Roberts KB, et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst (2013) 105(1):25-32. doi:10.1093/jnci/djs463
38. Fang P, Mick R, Deville C, Both S, Bekelman JE, Christodouleas JP, et al. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer. Cancer (2015) 121:1118-27. doi:10.1002/cncr.29148
39. Coen JJ, Bae K, Zietman AL, Patel B, Shipley WU, Slater JD, et al. Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II Study 03-12. Int J Radiat Oncol Biol Phys (2011) 81:1005-9. doi:10.1016/j.ijrobp.2010.06.047
40. Hoeller U, Tribius S, Kuhlmey A, Grader K, Fehlauer F, Alberti W. Increasing the rate of late toxicity by changing the score? A comparison of RTOG/EORTC and LENT/SOMA scores. Int J Radiat Oncol Biol Phys (2003) 55:1013-8. doi:10.1016/S0360-3016(02)04202-5
41. Faria SL, Aslani M, Tafazoli FS, Souhami L, Freeman CR. The challenge of scoring radiation-induced lung toxicity. Clin Oncol (2009) 21:371-5. doi:10.1016/j.clon.2009.01.017
42. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys (2003) 55:93-8. doi:10.1016/S0360-3016(02)03819-1
43. Bruce JY, Lang JM, McNeel DG, Liu G. Current controversies in the management of biochemical failure in prostate cancer. Clin Adv Hematol Oncol (2012) 10:716-22.
44. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys (2015) 37:1035-41. doi:10.1016/S0360-3016(97)00002-3
45. Barker JL Jr, Garden AS, Ang KK, O'Daniel JC, Wang H, Court LE, et al. Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. Int J Radiat Oncol Biol Phys (2004) 59:960-70. doi:10.1016/j.ijrobp.2003.12.024
46. Niemierko A. Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys (1997) 24:103-10. doi:10.1118/1.598154
47. Niemierko A. A generalized concept of equivalent uniform dose (EUD). Med Phys (1999) 26:1100.
48. Hope AJ, Lindsay PE, El Naqa I, Alaly JR, Vicic M, Bradley JD, et al. Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. Int J Radiat Oncol Biol Phys (2006) 65:112-24. doi:10.1016/j.ijrobp.2005.11.046
49. Acosta O, Dowling J, Cazoulat G, Simon A, Salvado O, de Crevoisier R, et al. Atlas based segmentation and mapping of organs at risk from planning CT for the development of voxel-wise predictive models of toxicity in prostate radiotherapy. In: Madabhushi A, Dowling J, Yan P, Fenster A, Abolmaesumi P, Hata N, editors. Prostate Cancer Imaging. Comput. Diagnosis, Progn. Interv. SE-6. (Vol. 6367), Berlin: Springer (2010). p. 42-51.
50. Sivanathan S, Jang S, Mittal BB, Luo J, Grein CH, Klie R, et al. A study of the radiobiological modeling of the conformal radiation therapy in cancer treatment. (2012). Available at: https://indigo.uic.edu/handle/10027/9467
51. Hakimi AA, Ostrovnaya I, Reva B, Schultz N, Chen YB, Gonen M, et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res (2013) 19:3259-67. doi:10.1158/1078-0432.CCR-12-3886
52. Svensson JP, Stalpers LJA, Lange REEE, Franken NAP, Haveman J, Klein B, et al. Analysis of gene expression using gene sets discriminates cancer patients with and without late radiation toxicity. PLoS Med (2006) 3:e422. doi:10.1371/journal.pmed.0030422
53. Barnett GC, Elliott RM, Alsner J, Andreassen CN, Abdelhay O, Burnet NG, et al. Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. Radiother Oncol (2012) 105:289-95. doi:10.1016/j.radonc.2012.10.017
54. Kerns SL, Ostrer H, Stock R, Li W, Moore J, Pearlman A, et al. Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2010) 78:1292-300. doi:10.1016/j.ijrobp.2010.07.036
55. Burri RJ, Stock RG, Cesaretti JA, Atencio DP, Peters S, Peters CA, et al. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiat Res (2008) 170:49-59. doi:10.1667/RR1219.1
56. Barnett GC, Coles CE, Burnet NG, Pharoah PDP, Wilkinson J, West CML, et al. No association between SNPs regulating TGF-β1 secretion and late radiotherapy toxicity to the breast: results from the RAPPER study. Radiother Oncol (2010) 97:9-14. doi:10.1016/j.radonc.2009.12.006
57. Defraene G, Van Den Bergh L, Al-Mamgani A, Haustermans K, Heemsbergen W, Van Den Heuvel F, et al. The benefits of including clinical factors in rectal normal tissue complication probability modeling after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2012) 82:1233-42. doi:10.1016/j.ijrobp.2011.03.056
58. Parliament MB, Murray D. Single nucleotide polymorphisms of DNA repair genes as predictors of radioresponse. Semin Radiat Oncol (2010) 20:232-40. doi:10.1016/j.semradonc.2010.05.003
59. Barnett GC, West CML, Dunning AM, Elliott RM, Coles CE, Pharoah PDP, et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer (2009) 9:134-42. doi:10.1038/nrc2587
60. Coates J, Jeyaseelan AK, Ybarra N, David M, Faria S, Souhami L, et al. Contrasting analytical and data-driven frameworks for radiogenomic modeling of normal tissue toxicities in prostate cancer. Radiother Oncol (2015) 115(1):107-13. doi:10.1016/j.radonc.2015.03.005
61. Peeters STH, Hoogeman MS, Heemsbergen WD, Hart AAM, Koper PCM, Lebesque JV. Rectal bleeding, fecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: normal tissue complication probability modeling. Int J Radiat Oncol Biol Phys (2006) 66:11-9. doi:10.1016/j.ijrobp.2006.03.034
62. Tucker SL, Li M, Xu T, Gomez D, Yuan X, Yu J, et al. Incorporating single-nucleotide polymorphisms into the lyman model to improve prediction of radiation pneumonitis. Int J Radiat Oncol Biol Phys (2013) 85:251-7. doi:10.1016/j.ijrobp.2012.02.021
63. Rancati T, Fiorino C, Fellin G, Vavassori V, Cagna E, Casanova Borca V, et al. Inclusion of clinical risk factors into NTCP modelling of late rectal toxicity after high dose radiotherapy for prostate cancer. Radiother Oncol (2011) 100:124-30. doi:10.1016/j.radonc.2011.06.032
64. Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med (2011) 17:330-9. doi:10.1038/nm.2305
65. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis (2009) 31:27-36. doi:10.1093/carcin/bgp220
66. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell (2012) 150:12-27. doi:10.1016/j.cell.2012.06.013
67. Smits KM, Melotte V, Niessen HEC, Dubois L, Oberije C, Troost EGC, et al. Epigenetics in radiotherapy: where are we heading? Radiother Oncol (2014) 111:168-77. doi:10.1016/j.radonc.2014.05.001
68. Muscarella LA, Parrella P, D'Alessandro V, la Torre A, Barbano R, Fontana A, et al. Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. Epigenetics (2011) 6:710-9. doi:10.4161/epi.6.6.15773
69. Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst (2005) 97:103-15. doi:10.1093/jnci/dji010
70. Li L-C. Epigenetics of prostate cancer. Front Biosci (2007) 12:3377-97. doi:10.2741/2320
71. Nightingale KP, O'Neill LP, Turner BM. Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr Opin Genet Dev (2006) 16:125-36. doi:10.1016/j.gde.2006.02.015
72. Turner BM. Defining an epigenetic code. Nat Cell Biol (2007) 9:2-6. doi:10.1038/ncb0107-2
73. Turner BM. Histone acetylation and an epigenetic code. Bioessays (2000) 22:836-45. doi:10.1002/1521-1878(200009)22:9<836:AID-BIES9>3.0.CO;2-X
74. Rakyan VK, Down TA, Balding DJ, Beck S. Epigenome-wide association studies for common human diseases. Nat Rev Genet (2011) 12:529-41. doi:10.1038/nrg3000
75. Lambin P, van Stiphout RGPM, Starmans MHW, Rios-Velazquez E, Nalbantov G, Aerts HJWL, et al. Predicting outcomes in radiation oncology-multifactorial decision support systems. Nat Rev Clin Oncol (2013) 10:27-40. doi:10.1038/nrclinonc.2012.196
76. Abd El-Rehim DM, Ball G, Finder SE, Rakha E, Paish C, Robertson JFR, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer (2005) 116:340-50. doi:10.1002/ijc.21004
77. Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol (2011) 29:17-24. doi:10.1200/JCO.2010.30.1077
78. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, Bemis L, et al. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol (2002) 20:2417-28. doi:10.1200/JCO.2002.08.159
79. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, et al. A microRNA signature of hypoxia. Mol Cell Biol (2007) 27:1859-67. doi:10.1128/MCB.01395-06
80. Buffa FM, Harris AL, West CM, Miller CJ. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer (2010) 102:428-35. doi:10.1038/sj.bjc.6605450
81. Chi J-T, Wang Z, Nuyten DSA, Rodriguez EH, Schaner ME, Salim A, et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med (2006) 3:e47. doi:10.1371/journal.pmed.0030047
82. Clarke R, Ressom HW, Wang A, Xuan J, Liu MC, Gehan EA, et al. The properties of high-dimensional data spaces: implications for exploring gene and protein expression data. Nat Rev Cancer (2008) 8:37-49. doi:10.1038/nrc2294
83. Alaiya AA, Franzén B, Auer G, Linder S. Cancer proteomics: from identification of novel markers to creation of artificial learning models for tumor classification. Electrophoresis (2000) 21:1210-7. doi:10.1002/(SICI)1522-2683(20000401)21:6<1210:AID-ELPS1210>3.0.CO;2-S
84. Kreso A, O'Brien CA, van Galen P, Gan OI, Notta F, Brown AMK, et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science (2013) 339:543-8. doi:10.1126/science.1227670
85. Eisen M. Mathematical Models in Cell Biology and Cancer Chemotherapy. (Vol. 30). Berlin: Springer Science & Business Media (2013).
86. Phillips TM, McBride WH, Pajonk F. The response of CD24-/low/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst (2006) 98:1777-85. doi:10.1093/jnci/djj495
87. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer (2005) 5:516-25. doi:10.1038/nrc1650
88. Lett JT. Damage to cellular DNA from particulate radiations, the efficacy of its processing and the radiosensitivity of mammalian cells. Radiat Environ Biophys (1992) 31:257-77. doi:10.1007/BF01210207
89. Coates J. Motivation for the inclusion of genetic risk factors of radiosensitivity alongside dosimetric and clinical parameters in predicting normal tissue effects. Acta Oncol (2015) 54:1230-1. doi:10.3109/0284186X.2014.999163
90. Jones B, Dale RG. Radiobiology of High Dose Fractions. Stereotact. Body Radiother. Berlin: Springer (2015). p. 67-86.
91. Guerrero M, Li XA. Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol (2004) 49:4825-35. doi:10.1088/0031-9155/49/20/012
92. Takahashi W, Nakajima M, Yamamoto N, Tsuji H, Kamada T, Tsujii H. Carbon ion radiotherapy in a hypofractionation regimen for stage I non-small-cell lung cancer. J Radiat Res (2014) 55:i26-7. doi:10.1093/jrr/rrt216
93. Webb S, Nahum AE. A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density. Phys Med Biol (1993) 38:653. doi:10.1088/0031-9155/38/6/001
94. Dale RG. Time-dependent tumour repopulation factors in linear-quadratic equations-implications for treatment strategies. Radiother Oncol (1989) 15:371-81. doi:10.1016/0167-8140(89)90084-4
95. Tilly N, Brahme A, Carlsson J, Glimelius B. Comparison of cell survival models for mixed LET radiation. Int J Radiat Biol (1999) 75:233-43. doi:10.1080/095530099140690
96. Ling CC, Chen CH, Fuks Z. An equation for the dose response of radiation-induced apoptosis: possible incorporation with the LQ model. Radiother Oncol (1994) 33:17-22. doi:10.1016/0167-8140(94)90081-7
97. Wang JZ, Huang Z, Lo SS, Yuh WTC, Mayr NA. A generalized linear-quadratic model for radiosurgery, stereotactic body radiation therapy, and high-dose rate brachytherapy. Sci Transl Med (2010) 2:39ra48. doi:10.1126/scitranslmed.3000864
98. Kellerer AM, Rossi HH. The theory of dual radiation action. Curr Top Radiat Res (1974) VIII:85-158.
99. Dale RG, Jones B. The assessment of RBE effects using the concept of biologically effective dose. Int J Radiat Oncol Biol Phys (1999) 43:639-45. doi:10.1016/S0360-3016(98)00364-2
100. Carabe-Fernandez A, Dale RG, Jones B. The incorporation of the concept of minimum RBE (RbEmin) into the linear-quadratic model and the potential for improved radiobiological analysis of high-LET treatments. Int J Radiat Biol (2007) 83:27-39. doi:10.1080/09553000601087176
101. Sachs RK, Hahnfeld P, Brenner DJ. Review the link between low-LET dose-response relations and the underlying kinetics of damage production/repair/misrepair. Int J Radiat Biol (1997) 72:351-74. doi:10.1080/095530097143149
102. Zaider M, Hanin L. Tumor control probability in radiation treatment. Med Phys (2011) 38:574-83. doi:10.1118/1.3521406
103. Gagliardi G, Bjöhle J, Lax I, Ottolenghi A, Eriksson F, Liedberg A, et al. Radiation pneumonitis after breast cancer irradiation: analysis of the complication probability using the relative seriality model. Int J Radiat Oncol Biol Phys (2000) 46:373-81. doi:10.1016/S0360-3016(99)00420-4
104. Boersma LJ, Damen EMF, De Boer RW, Muller SH, Olmos RAV, Van Zandwijk N, et al. Estimation of overall pulmonary function after irradiation using dose-effect relations for local functional injury. Radiother Oncol (1995) 36:15-23. doi:10.1016/0167-8140(95)01580-A
105. Rancati T, Fiorino C, Gagliardi G, Cattaneo GM, Sanguineti G, Borca VC, et al. Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101). Radiother Oncol (2004) 73:21-32. doi:10.1016/j.radonc.2004.08.013
106. Kutcher GJ, Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys (1989) 16:1623-30. doi:10.1016/0360-3016(89)90972-3
107. Stavrev P, Stavreva N, Niemierko A, Goitein M. Generalization of a model of tissue response to radiation based on the idea of functional subunits and binomial statistics. Phys Med Biol (2001) 46:1501-18. doi:10.1088/0031-9155/46/5/312
108. Niemierko A, Goitein M. Modeling of normal tissue response to radiation: the critical volume model. Int J Radiat Oncol Biol Phys (1993) 25:135-45. doi:10.1016/0360-3016(93)90156-P
109. Stavrev P, Stavreva N, Sharplin J, Fallone BG, Franko A. Critical volume model analysis of lung complication data from different strains of mice. Int J Radiat Biol (2005) 81:77-88. doi:10.1080/09553000400027910
110. Yaes RJ, Kalend A. Local stem cell depletion model for radiation myelitis. Int J Radiat Oncol Biol Phys (1988) 14:1247-59. doi:10.1016/0895-7177(88)90651-6
111. Jackson A, Ten Haken RK, Robertson JM, Kessler ML, Kutcher GJ, Lawrence TS. Analysis of clinical complication data for radiation hepatitis using a parallel architecture model. Int J Radiat Oncol Biol Phys (1995) 31:883-91. doi:10.1016/0360-3016(94)00471-4
112. Hartford AC, Niemierko A, Adams JA, Urie MM, Shipley WU. Conformal irradiation of the prostate: estimating long-term rectal bleeding risk using dose-volume histograms. Int J Radiat Oncol Biol Phys (1996) 36:721-30. doi:10.1016/S0360-3016(96)00366-5
113. Lebesque JV, Bruce AM, Kroes APG, Touw A, Shouman T, Van Herk M. Variation in volumes, dose-volume histograms, and estimated normal tissue complication probabilities of rectum and bladder during conformal radiotherapy of T3 prostate cancer. Int J Radiat Oncol Biol Phys (1995) 33:1109-19. doi:10.1016/0360-3016(95)00253-7
114. Adamus-Górka M, Mavroidis P, Lind BK, Brahme A. Comparison of dose response models for predicting normal tissue complications from cancer radiotherapy: application in rat spinal cord. Cancers (Basel) (2011) 3:2421-43. doi:10.3390/cancers3022421
115. Tomczak J. Prediction of breast cancer recurrence using classification restricted boltzmann machine with dropping. arXiv (2013) 13086324:1-9.
116. Lee S, Ybarra N, Jeyaseelan K, Seuntjens J, El Naqa I, Faria S, et al. Bayesian network ensemble as a multivariate strategy to predict radiation pneumonitis risk. Med Phys (2015) 42:2421-30. doi:10.1118/1.4915284
117. van der Schaaf A, Langendijk JA, Fiorino C, Rancati T. Embracing phenomenological approaches to normal tissue complication probability modeling: a question of method. Int J Radiat Oncol Biol Phys (2015) 91:468-71. doi:10.1016/j.ijrobp.2014.10.017
118. van der Schaaf A, Xu C-J, van Luijk P, van't Veld AA, Langendijk JA, Schilstra C. Multivariate modeling of complications with data driven variable selection: guarding against overfitting and effects of data set size. Radiother Oncol (2012) 105:115-21. doi:10.1016/j.radonc.2011.12.006
119. Anagnostou T, Remzi M, Lykourinas M, Djavan B. Artificial neural networks for decision-making in urologic oncology. Eur Urol (2003) 43:596-603. doi:10.1016/S0302-2838(03)00133-7
120. Djavan B, Remzi M, Zlotta A, Seitz C, Snow P, Marberger M. Novel artificial neural network for early detection of prostate cancer. J Clin Oncol (2002) 20:921-9. doi:10.1200/JCO.20.4.921
121. Jerez-Aragonés JM, Gómez-Ruiz JA, Ramos-Jiménez G, Muñoz-Pérez J, Alba-Conejo E. A combined neural network and decision trees model for prognosis of breast cancer relapse. Artif Intell Med (2003) 27:45-63. doi:10.1016/S0933-3657(02)00086-6
122. Schwarzer G, Vach W, Schumacher M. On the misuses of artificial neural networks for prognostic and diagnostic classification in oncology. Stat Med (2000) 19:541-61. doi:10.1002/(SICI)1097-0258(20000229)19:4<541:AID-SIM355>3.0.CO;2-V
123. Tomatis S, Rancati T, Fiorino C, Vavassori V, Fellin G, Cagna E, et al. Late rectal bleeding after 3D-CRT for prostate cancer: development of a neural-network-based predictive model. Phys Med Biol (2012) 57:1399-412. doi:10.1088/0031-9155/57/5/1399
124. Whitley D, Starkweather T, Bogart C. Genetic algorithms and neural networks: optimizing connections and connectivity. Parallel Comput (1990) 14:347-61. doi:10.1016/0167-8191(90)90086-O
125. Belew RK, McInerney J, Schraudolph NN. Evolving networks: using the genetic algorithm with connectionist learning. Artif Life II (1992) 10:511-47.
126. Su M, Miften M, Whiddon C, Sun X, Light K, Marks L. An artificial neural network for predicting the incidence of radiation pneumonitis. Med Phys (2005) 32:318-25. doi:10.1118/1.1835611
127. Chen S, Zhou S, Zhang J, Yin F-F, Marks LB, Das SK. A neural network model to predict lung radiation-induced pneumonitis. Med Phys (2007) 34:3420-7. doi:10.1118/1.2759601
128. Specht DF. A general regression neural network. IEEE Trans Neural Networks (1991) 2:568-76. doi:10.1109/72.97934
129. Blanco AI, Chao KSC, El Naqa I, Franklin GE, Zakarian K, Vicic M, et al. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. Int J Radiat Oncol Biol Phys (2005) 62:1055-69. doi:10.1016/j.ijrobp.2004.12.076
130. Hoffmann H. Kernel PCA for novelty detection. Pattern Recognit (2007) 40:863-74. doi:10.1016/j.patcog.2006.07.009
131. Mika S, Schölkopf B, Smola A, Müller K, Scholz M, Rätsch G. Kernel PCA and de-noising in feature spaces. Analysis (1999) 11:536-42.
132. Schölkopf B, Smola A, Müller K-R. Kernel principal component analysis. In: Gerstner W, Germond A, Hasler M, Nicoud J-D, editors. Artif. Neural Networks-ICANN'97 SE-93. (Vol. 1327), Berlin: Springer (1997). p. 583-8.
133. El Naqa I. Outcomes modeling (Chapter 24). In: Starkschall G, Siochi C, editors. Informatics in Radiation Oncology. Boca Raton, FL (2013). p. 257-76.
134. Kitano H. Systems biology: a brief overview. Science (2002) 295:1662-4. doi:10.1126/science.1069492
135. Weston AD, Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine introduction: paradigm changes in health care. J Proteome Res (2004) 3(2):179-96. doi:10.1021/pr0499693
136. Laubenbacher R, Hower V, Jarrah A, Torti SV, Shulaev V, Mendes P, et al. A systems biology view of cancer. Biochim Biophys Acta Rev Cancer (2009) 1796:129-39. doi:10.1016/j.bbcan.2009.06.001
137. Feinendegen L, Hahnfeldt P, Schadt EE, Stumpf M, Voit EO. Systems biology and its potential role in radiobiology. Radiat Environ Biophys (2007) 47:5-23. doi:10.1007/s00411-007-0146-8
138. Unger K. Integrative radiation systems biology. Radiat Oncol (2014) 9:21. doi:10.1186/1748-717X-9-21
139. Smith WP, Doctor J, Meyer J, Kalet IJ, Phillips MH. A decision aid for intensity-modulated radiation-therapy plan selection in prostate cancer based on a prognostic Bayesian network and a Markov model. Artif Intell Med (2009) 46:119-30. doi:10.1016/j.artmed.2008.12.002
140. Oh JH, Craft J, Al Lozi R, Vaidya M, Meng Y, Deasy JO, et al. A Bayesian network approach for modeling local failure in lung cancer. Phys Med Biol (2011) 56:1635-51. doi:10.1088/0031-9155/56/6/008
141. Messer JA, Mohamed ASR, Hutcheson KA, Ding Y, Lewin JS, Wang J, et al. Magnetic resonance imaging of swallowing-related structures in nasopharyngeal carcinoma patients receiving IMRT: longitudinal dose-response characterization of quantitative signal kinetics. Radiother Oncol (2016) 118:315-22. doi:10.1016/j.radonc.2016.01.011
142. El Naqa I, Suneja G, Lindsay PE, Hope AJ, Alaly JR, Vicic M, et al. Dose response explorer: an integrated open-source tool for exploring and modelling radiotherapy dose-volume outcome relationships. Phys Med Biol (2006) 51:5719-35. doi:10.1088/0031-9155/51/22/001
143. Aho K, Derryberry D, Peterson T. Model selection for ecologists: the worldviews of AIC and BIC. Ecology (2014) 95:631-6. doi:10.1890/13-1452.1
144. Akaike H. Information theory and an extension of the maximum likelihood principle. 2nd International Symposium on Information Theory. Budapest: Akademiai Kiado (1973). p. 267-81.
145. Schwarz G. Estimating the dimension of a model. Ann Stat (1978) 6:461-4. doi:10.1214/aos/1176344136
146. Kass RE, Raftery AE. Bayes factors. J Am Stat Assoc (1995) 90(430):773-95.
147. Coates J, Jeyaseelan AK, Ybarra N, Tao J, David M, Faria S, et al. Evaluation and visualization of radiogenomic modeling frameworks for the prediction of normal tissue toxicities. In: Jaffray DA, editor. World Congr. Med. Phys. Biomed. Eng. June 7-12, 2015, Toronto, Canada. Berlin: Springer International Publishing (2015). p. 517-20.
148. Deasy JO, Bentzen SM, Jackson A, Ten Haken RK, Yorke ED, Constine LS, et al. Improving normal tissue complication probability models: the need to adopt a "data-pooling" culture. Int J Radiat Oncol Biol Phys (2010) 76:S151-4. doi:10.1016/j.ijrobp.2009.06.094
149. Li XA, Alber M, Deasy JO, Jackson A, Jee K-WK, Marks LB, et al. The use and QA of biologically related models for treatment planning: short report of the TG-166 of the therapy physics committee of the AAPM. Med Phys (2012) 39:1386-409. doi:10.1118/1.3685447
150. Sanchez-Nieto B, Nahum AE. BIOPLAN: software for the biological evaluation of. Radiotherapy treatment plans. Med Dosim (2000) 25:71-6. doi:10.1016/S0958-3947(00)00031-5
151. Deasy JO, Blanco AI, Clark VH. CERR: a computational environment for radiotherapy research. Med Phys (2003) 30:979-85. doi:10.1118/1.1568978
152. Zietman A. Proton beam and prostate cancer: an evolving debate. Reports Pract Oncol Radiother (2013) 18:338-42. doi:10.1016/j.rpor.2013.06.001
153. Paganetti H, Niemierko A, Ancukiewicz M, Gerweck LE, Goitein M, Loeffler JS, et al. Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys (2002) 53:407-21. doi:10.1016/S0360-3016(02)02754-2
154. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/American College of Radiology 95-09. J Clin Oncol (2010) 28:1106-11. doi:10.1200/JCO.2009.25.8475
155. Ishikawa H, Tsuji H, Kamada T, Yanagi T, Mizoe J-E, Kanai T, et al. Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study. Radiother Oncol (2006) 81:57-64. doi:10.1016/j.radonc.2006.08.015
156. Tsuji H, Yanagi T, Ishikawa H, Kamada T, Mizoe J, Kanai T, et al. Hypofractionated radiotherapy with carbon ion beams for prostate cancer. Int J Radiat Oncol Biol Phys (2005) 63:1153-60. doi:10.1016/j.ijrobp.2005.04.022
157. Slater JD, Rossi CJ, Yonemoto LT, Bush DA, Jabola BR, Levy RP, et al. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys (2004) 59:348-52. doi:10.1016/j.ijrobp.2003.10.011
158. Talcott JA, Rossi C, Shipley WU, Clark JA, Slater JD, Niemierko A, et al. Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. J Urol (2010) 184:1993. doi:10.1016/j.juro.2010.07.024
159. Fontana AO, Augsburger MA, Grosse N, Guckenberger M, Lomax AJ, Sartori AA, et al. Differential DNA repair pathway choice in cancer cells after proton-and photon-irradiation. Radiother Oncol (2015) 116(3):374-80. doi:10.1016/j.radonc.2015.08.014
160. Gerelchuluun A, Manabe E, Ishikawa T, Sun L, Itoh K, Sakae T, et al. The major DNA repair pathway after both proton and carbon-ion radiation is NHEJ, but the HR pathway is more relevant in carbon ions. Radiat Res (2015) 183:345-56. doi:10.1667/RR13904.1
161. Tomczak JM. Application of classification restricted Boltzmann machine to medical domains. International Conference on Innovative Trends in Science, Engineering and Management (ICITSEM 2014). Dubai, UAE: (2014).
162. Menze B, Langs G, Montillo A, Kelm M, Müller H, Zhang S, et al. Medical Computer Vision: Algorithms for Big Data: International Workshop, MCV 2014, Held in Conjunction with MICCAI 2014. Cambridge, MA: Springer (2014). [Revised Selected Papers. vol. 8848].
163. Koziol JA, Tan EM, Dai L, Ren P, Zhang J-Y. Restricted Boltzmann machines for classification of hepatocellular carcinoma. Comput Biol J (2014) 2014:5. doi:10.1155/2014/418069
164. Hinton GE, Salakhutdinov RR. Reducing the dimensionality of data with neural networks. Science (2006) 313:504-7. doi:10.1126/science.1127647
165. Kumar D, Wong A, Clausi DA. Lung nodule classification using deep features in CT images. Comput. Robot Vis. (CRV), 2015 12th Conf., IEEE. Halifax, NS (2015). p. 133-8.
166. Liang M, Li Z, Chen T, Zeng J. Integrative data analysis of multi-platform cancer data with a multimodal deep learning approach. IEEE/ACM Trans Comput Biol Bioinform (2015) 12:928-37. doi:10.1109/TCBB.2014.2377729